Biomea Fusion (BMEA) vs Rallybio (RLYB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Rallybio (RLYB) has outperformed Biomea Fusion (BMEA) over the past year, gaining 208.4% versus a loss of 41.5%. Over five years, RLYB leads with a -85.3% price change compared with -95.2% for BMEA. Rallybio is the larger company by market cap ($43.3 million vs $41.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BMEA | RLYB |
|---|---|---|
| Share price | $0.5744 | $15.47 |
| Market cap | $41.75M | $43.32M |
| 1-day change | -2.38% | -0.32% |
| YTD return | -53.68% | +181.89% |
| 1-year return | -41.51% | +208.41% |
| 5-year return | -95.21% | -85.29% |
| P/E ratio (TTM) | — | 3.36 |
| EPS (TTM) | $-0.10 | $4.61 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $858.00K |
| Revenue growth (YoY) | — | +34.91% |
| Net income (latest FY) | $-61.80M | $-8.98M |
| Operating margin | — | -3853.61% |
| Net margin | — | -1046.39% |
| 52-week high | $2.24 | $35.15 |
| 52-week low | $0.45 | $7.34 |
| Distance from 52-week high | -74.32% | -55.99% |
| Analyst consensus | buy | — |
| Avg. price target upside | +1118.66% | — |
| Average volume | 2.22M | 10.14K |
| Shares outstanding | 72.68M | 2.80M |
| Employees | 37 | 7 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RLYB has outperformed BMEA by 249.9 percentage points over the past year.
About Biomea Fusion
BMEA stock →Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes.
Health Care · Biotechnology: Pharmaceutical Preparations · 37 employees
About Rallybio
RLYB stock →Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
BMEA vs RLYB FAQ
Which is bigger, Biomea Fusion or Rallybio?
Rallybio (RLYB) is larger, with a market capitalization of $43.32M compared with $41.75M for Biomea Fusion (BMEA).
Which stock has performed better over the past year, BMEA or RLYB?
RLYB returned +208.41% over the past 12 months, compared with -41.51% for BMEA (price return, excluding dividends). Past performance does not predict future results.
Are Biomea Fusion and Rallybio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.